A case of concomitant <i>EGFR/ALK</i> alteration against a mutated <i>EGFR</i> background in early-stage lung adenocarcinoma
Journal of Pathology and Translational Medicine. 2021;55(2):139-144 
Treatment Strategy of Lung Adenocarcinoma with Concomitant EGFR Mutation and ALK Rearrangement
. 2021;
Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: Report of a case and review of the literature with demonstration of genes alteration into the same tumor cells
Lung Cancer. 2014;86(2):291-295
EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib
Lung Cancer. 2017;108:45-47
Efficacy Differences of First-line EGFR-TKIs Alone vs. in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alteration(s)
. 2021;
Gefitinib
Reactions Weekly. 2017;1675(1):117-117
Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report
Diagnostic Pathology. 2020;15(1):
Gefitinib
Reactions Weekly. 2019;1778(1):214-214
Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML
Case Reports in Oncological Medicine. 2020;2020:1-6
NSE level in combined neuroendocrine and adenocarcinoma EGFR mutated lung cancer resistant to EGFR-TKI
Lung Cancer. 2013;82(1):177-178